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ABSTRACT
Preoperative staging of gastric cancer with computed tomography alone exhibits 
poor diagnostic accuracy, which may lead to improper treatment decisions. We 
developed novel patient stratification criteria to select appropriate treatments for 
gastric cancer patients based on preoperative staging and clinicopathologic features. 
A total of 5352 consecutive patients who underwent gastrectomy for gastric cancer 
were evaluated. Preoperative stages were determined according to depth of invasion 
and nodal involvement on computed tomography. Logistic regression analysis was 
used to identify clinicopathological factors associated with the likelihood of proper 
patient stratification. The diagnostic accuracies of computed tomography scans for 
depth of invasion and nodal involvement were 67.1% and 74.1%, respectively. Among 
clinicopathologic factors, differentiated tumor histology, tumors smaller than 5 cm, 
and gross appearance of early gastric cancer on endoscopy were shown to be related 
to a more advanced stage of disease on preoperative computed tomography imaging 
than actual pathological stage. Additional consideration of undifferentiated histology, 
tumors larger than 5 cm, and grossly advanced gastric cancer on endoscopy increased 
the probability of selecting appropriate treatment from 75.5% to 94.4%. The addition 
of histology, tumor size, and endoscopic findings to preoperative staging improves 
patient stratification for more appropriate treatment of gastric cancer.
INTRODUCTION
A global health problem, gastric cancer ranks as 
the third most common cause of cancer-related deaths 
worldwide [1]. Despite efforts to improve early detection 
of gastric cancer by mass screening in Korea and Japan, 
the proportion of advanced gastric cancers still remains 
high at 39.2%-51.4% [2-4]. Indeed, the incidence of 
advanced gastric cancer is much higher in Western 
countries [2, 5]. Consequently, developing treatment 
strategies for patients with advanced gastric cancer has 
emerged as a major concern, and multimodal treatments, 
such as neoadjuvant chemotherapy and perioperative or 
preoperative chemoradiotherapy, have been applied for the 
treatment of advanced gastric cancer.
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Major guidelines for gastric cancer treatment 
recommend that decisions are to be made based on clinical 
staging, primarily achieved with the use of computed 
tomography (CT) [6-8]. With advances in equipment, 
development of contrast materials, and applications of 
stomach cancer-specific protocols, the diagnostic accuracy 
of CT scans for gastric cancer has improved considerably. 
The overall diagnostic accuracies of CT scans in predicting 
tumor depth and nodal status range from 71.4% to 88.9% 
and 75.9% to 78%, respectively [9-12]. Nevertheless, such 
accuracies are insufficient for proper treatment decisions. 
Moreover, studies on preoperative, multimodal treatments 
have included patients with pathologically early stage 
gastric cancer who do not require any perioperative or 
preoperative chemotherapy.
Although many studies have evaluated the accuracy 
of clinical staging using CT scans for gastric cancer, most 
have analyzed its accuracy in regards to depth of invasion 
or nodal status separately. Few studies have focused on 
evaluating diagnostic accuracy in relation to overall 
clinical staging. Furthermore, no study has attempted to 
identify risk factors for inappropriate treatment decisions 
caused by inaccurate clinical staging, and no study has 
evaluated clinicopathologic features that may help 
improve patient stratification for proper decision making.
In the present study, we hypothesized that additional 
consideration of clinicopathologic features in clinical 
staging would facilitate proper patient stratification for 
gastric cancer treatment. Accordingly, we compared 
preoperative clinical stages to their actual pathologic 
stages to investigate the diagnostic accuracy of clinical 
staging with CT alone in gastric cancer and then evaluated 
which clinicopathologic features improved the diagnostic 
accuracy thereof. Additionally, we attempted to develop 
novel patient stratification criteria to select appropriate 
treatment modalities for gastric cancer patients based on 
preoperative staging and clinicopathologic factors found 
to be associated with improved diagnostic accuracy.
RESULTS
Patient characteristics
Patient demographics and clinicopathological 
characteristics are summarized in Table 1. There were 
3491 men and 1861 women in the current study. The 
mean age was 57.9 ± 11.9 years. The mean tumor size 
was 3.6 ± 2.7cm. The tumors were located mainly in the 
lower third (58.8%) and lesser curvature (43.5%) of the 
stomach. Histologically, undifferentiated tumors were 
predominant (56.6%), compared to differentiated ones 
(43.4%). In preoperative clinical staging based on analysis 
of CT images, the majority of patients were classified as 
clinical T1 stage (52.3%) and clinical N- stage (69.4%). 
On pathological staging, T1 (56.3%) and N-(64.5%) 
tumors were most common.
Accuracy of preoperative staging
A comparison of T classification between the 
preoperative CT scans and final pathologic results is 
shown in Table 2. The accuracy of T classification was 
Figure 1: Flow diagram of study patients.
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Table 1: Demographics and clinicopathological features.
Variable N = 5352 %
Age (years) 57.9 ± 11.9
Gender
   Male 3491 65.2
   Female 1861 34.8
Body mass index (kg/m2) 23.3 ± 2.9
Tumor size (cm) 3.64 ± 2.65
Gross finding
   EGC 3046 56.9
   AGC 2306 43.1
Ulceration
   Absent 1910 35.7
   Present 3442 64.3
Histology
   Differentiated 2324 43.4
   Undifferentiated 3028 56.6
Location, circular
   Lesser curvature 2329 43.5
   Greater curvature 735 13.7
   Anterior wall 1061 19.8
   Posterior wall 1178 22.0
   Encircling 49 0.9
Location, tubular
   Upper 682 12.7
   Middle 1514 28.3
   Lower 3147 58.8
   Entire 9 0.2
EGC, early gastric cancer; AGC, advanced gastric cancer
Table 2: Correlation of clinical and pathologic stage for depth of invasion and nodal status.
Depth of invasion pT1( N =3013)
pT2/T3
(N = 1244)
pT4
(N = 1095)
Total
(N = 5352)
cT1 2392 319 86 2797
cT2–3 506 554 364 1424
cT4 115 371 645 1131
k value 0.65
Nodal involvement pN(-)(N = 3454)
pN(+)
(N = 1898)
Total
(N = 5352)
cN(-) 2891 821 3712
cN(+) 563 1077 1640
Sensitivity 65.6 %
Specificity 83.7 %
pT, pathological T staging; cT, clinical T staging; pN, pathological N staging; cN, clinical N staging; pT/N, overall pathological 
staging; cT/N, overall clinical staging.
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67.1%, with overestimation occurring in 18.5% of 
patients and underestimation occurring in 14.4% of 
patients. The reliability for tumor depth was k = 0.65. 
The cT2-3 classification subgroup showed the highest 
percentage of overestimation (35.5%, 506/1424). The 
accuracy of preoperative N classification was 74.1% 
(3968/5352). Overestimation and underestimation of 
N classification reached 10.5% (563/5352) and 15.4% 
(821/5352), respectively. The sensitivity and specificity 
for clinical node involvement (cN+) were 65.6% and 
83.7%, respectively. A comparison between preoperative 
and postoperative staging is shown in Table 3. The 
accuracy of overall staging was 53.3%; overestimation and 
underestimation reached 23.9% and 22.8%, respectively. 
The reliability for overall staging was k = 0.69.
In multivariate analysis of the cApE and cApA 
groups, undifferentiated histology (p < .001), tumors 
larger than 5 cm (p <.001), and grossly advanced gastric 
cancer (AGC) appearance on endoscopy (p <.001) were 
independently associated with a higher probability of 
proper patient stratification for treatment (cApA group) 
(Table 4).
Probability for proper patient stratification
The probability of proper patient stratification 
was 75.5%, calculated as the number of patients in the 
cApA group (n = 1243) divided by the number in both the 
cApE and cApA groups (n = 1646) (Table 5). When we 
additionally considered the clinicopathological features 
found to be related to diagnostic accuracy in our study, 
Figure 2: Classification of patients to establish proper selection criteria for treatment modalities. The clinical early and 
pathological early stage (cEpE) group (green color), the clinical early and pathological advanced stage (cEpA) group (gray color), the 
clinical advanced and pathological early stage (cApE) group (brown color), and the clinical advanced and pathological advanced stage 
(cApA) group (yellow color).
Table 3: Correlation of overall clinical and pathologic stage.
Stage grouping pT1/N(-)(N = 2700)
pT1/N(+)
(N = 313)
pT2–3/N(-)
(N = 565)
pT2–3/N(+)
(N = 679)
pT4/N(-)
(N = 189)
pT4/N(+)
(N = 906)
Total
(N = 5352)
cT1/N(-) 2017 166 168 86 26 38 2501
cT1/N(+) 175 34 31 34 5 17 296
cT2–3/N(-) 338 54 192 148 46 131 909
cT2–3/N(+) 78 36 67 147 36 151 515
cT4/N(-) 36 6 39 56 29 136 302
cT4/N(+) 56 17 68 208 47 433 829
k value 0.69
pT, pathological T staging; cT, clinical T staging; pN, pathological N staging; cN, clinical N staging; pT/N, overall pathological 
staging; cT/N, overall clinical staging.
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the probability of proper patient stratification greatly 
improved. By considering only one additional feature 
(histology, size, or gross appearance), the probability 
of proper patient stratification improved from 75.5% to 
81.2%-89.3%. Moreover, if two variables were considered, 
the probability increased to 88.0%-92.5%. Among patients 
with undifferentiated histology, tumors larger than 5 cm, 
and gross AGC appearance on endoscopy, the probability 
of proper patient stratification improved to 94.4%: in 
other words, candidates receiving potentially unnecessary 
neoadjuvant chemotherapy could be decreased from 403 
patients (403/5352) to 30 patients (30/5352). Meanwhile, 
the probability of proper patient stratification was only 
10.5% in patients who had differentiated histology, 
tumors smaller than 5 cm, and early gastric cancer (EGC) 
appearance on endoscopy.
DISCUSSION
In the present study, the accuracies of estimating 
depth of invasion and nodal involvement on CT scans 
alone were 67.1% and 74.1%, respectively. The accuracy 
of overall staging was only 53.3%. More specifically, 
35.5% and 34.3% of patients were overestimated 
for clinical T2-3 classification and node positivity, 
respectively. When we additionally considered the 
clinicopathologic features identified in our study to be 
associated with proper patient stratification, the probability 
thereof improved from 75.5% to 94.4%.
When deciding on a treatment modality before 
Table 4: Clinicopathological features related to probability of proper patient stratification. 
OR, odds ratio; EGC, early gastric cancer; AGC, advanced gastric cancer.
A*: Clinical early advancedwith pathological advanced early group.
B†: Clinical advanced with pathological advanced group. 
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surgery, physicians must take into account the integrated 
clinical stage of each patient; however, preoperative 
staging based on CT scans alone can be inaccurate. 
Nevertheless, few studies have attempted to evaluate the 
accuracy of overall clinical staging using CT scans alone. 
In the current study, we found that the accuracy thereof in 
gastric cancer patients was only 53.3%.
Treatment modalities are commonly selected 
according to clinical stage. Japanese gastric cancer 
treatment guidelines state that there is no established 
benefit of neoadjuvant chemotherapy for gastric cancer 
patients. Meanwhile, Western guidelines recommend 
neoadjuvant chemotherapy or surgery for patients with 
stage II disease or higher (cT2-3N+ or cT4N-/+) [13]. 
The present study, however, found that the probability 
of delivering inappropriate treatment was 24.5% when 
relying on CT scans alone to conduct preoperative clinical 
staging. When we considered clinicopathologic features 
of histology, tumor size, and endoscopic findings, the 
probability of delivering an inappropriate treatment 
modality decreased to 5.6%.
Our results indicate that undifferentiated histology, 
tumors larger than 5 cm, and grossly AGC appearance 
on endoscopy are independently associated with a higher 
probability of reaching a proper treatment decision. To the 
best of our knowledge, this study is the first to evaluate 
clinicopathologic features that can improve stratification 
of patients with gastric cancer. When we applied the 
identified clinicopathologic features, the likelihood of 
proper patient stratification increased from 75.5% to 
94.4%. Therefore, by considering these clinicopathologic 
features, physicians can spare patients with early staged 
tumors, who can be cured by surgery alone, from 
unnecessary pretreatment.
Neoadjuvant chemotherapy has been commonly 
used to treat resectable gastric cancer in Western countries. 
Its application is based on two large phase III clinical 
trials [13, 14], which demonstrated that perioperative 
chemotherapy facilitated significant improvements in 
resectability, disease-free survival, and overall survival, 
compared to surgery alone. However, despite these 
favorable results, the studies were critically limited in that 
no standard clinical staging method was applied at the 
time of randomization. As a result, patients in the surgery-
only group with pT1 and pN- classification comprised 
8.3% and 26.9%, respectively, of patients in the MAGIC 
trial [13]. Also, in the FNCLCC/FFCD trial [14], patients 
with a pN- classification accounted for 20% of the surgery-
only group [13, 14]. This means that similar proportions 
of patients that did not need chemotherapy were included 
in the perioperative chemotherapy groups in those studies. 
Accordingly, physicians should caution against applying 
unnecessary neoadjuvant chemotherapy to early stage 
patients, as doing so introduces greater medical expense, 
causes suffering due to serious side effects, and postpones 
the timing of surgery. By applying the clinicopathologic 
risk factors shown to be significant for proper patient 
satisfaction in the current study, which are readily 
collected during routine patient evaluations, physicians 
can protect their patients from unnecessary neoadjuvant 
chemotherapy. In our study, the number of candidates 
receiving unnecessary neoadjuvant chemotherapy could 
have been decreased from 403 to 30 patients among 5352 
patients.
This study is superior to previous studies for the 
following reasons: First, we utilized data from a large-
scale database collected over a relatively short period. 
Additionally, CT scans and resected specimens were 
evaluated, respectively, by radiologists and pathologists 
specializing in upper gastroenterology at a single, 
high-volume center. As well, preoperative staging was 
evaluated using CT scans acquired following a stomach 
cancer-specific protocol. Therefore, the data were of 
similar quality and highly reliable.
Table 5: Probability of proper patient stratification when considering clinicopathological features. 
(N) Clinical advanced and pathological early group
Clinical advanced and pathological 
advanced group Probability (%)
Variable not considered 403 1243 75.5
One variable considered
AGC§ 211 1204 85.1
> 5 cm* 88 738 89.3
Undiff† 196 847 81.2
Two variables considered
AGC§ + > 5 cm* 59 724 92.5
> 5 cm* + Undiff† 46 520 91.9
Undiff† + AGC§ 111 820 88.0
Three variables considered
AGC§ + > 5 cm* + Undiff† 30 507 94.4
AGC§: grossly advanced gastric cancer appearance in endoscopy; > 5 cm*: tumor size larger than 5 cm; Undiff†: 
undifferentiated histology.
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Notwithstanding, there are several limitations to the 
current study that warrant consideration. First, there may 
be bias in our study due to the retrospective nature of the 
analyses, although we used a large-scale, homogenous 
database. First, there may be bias in our study due to the 
retrospective nature of the analyses, although we used a 
large-scale, homogenous database. Additionally, our use 
of two different gastric distension methods could have 
affected the evaluation of clinical T classification, and the 
possibility of inter-radiologist differences in evaluation of 
CT images could not be excluded, although we used the 
same criteria for clinical T and N classification. Therefore, 
bias in deciding clinical T and N factors could not be 
completely avoided. Moreover, since we excluded patients 
who received neoadjuvant chemotherapy, bias related 
to this exclusion might be present in the analysis cApE 
and cApA patients. Second, we did not consider other 
diagnostic modalities, such as diagnostic laparoscopy and 
endoscopic ultrasound. If additional diagnostic tools were 
included for preoperative staging, diagnostic accuracy 
may have been increased. Nevertheless, CT scans are 
non-invasive and are currently regarded as a standard 
staging method. It is, therefore, worth noting that a simple 
combination of CT scans and clinicopathologic features 
improves patient stratification. Third, the preoperative 
nodal staging system utilized in this study differed 
from the AJCC pathologic staging system. Although we 
recognized differences between the two systems, we were 
unable to take them into account due to the retrospective 
design of our study. Further prospective studies with 
various diagnostic modalities are necessary to validate 
our findings. Fourth, using the three factors we have 
identified, underdiagnosis would likely be increased. 
However, surgery with adjuvant chemotherapy would 
not be considered undertreatment, rather it is a standard 
treatment option for stage II or III gastric cancer patients. 
Since the purpose of this study was to develop novel 
stratification criteria with which to select proper gastric 
cancer patients for neoadjuvant chemotherapy, we have 
focused on clinically advanced cancers. Lastly, due to the 
retrospective nature of the study, we discerned histology 
from pathologic evaluation of resected specimens. Thus, 
the possibility of changes in histologic type after resection 
must be considered, although discrepancies in histologic 
diagnosis between biopsy and pathologies of resected 
specimens reportedly range only from 2.4% to 4.4% [15-
17]. 
Current practices for treating gastric cancer 
based on preoperative staging with CT scans alone are 
associated with a high probability of improper treatment 
decisions due to low diagnostic accuracy. By additionally 
considering clinicopathologic features of histology, tumor 
size, and endoscopic findings, more appropriate treatment 
strategies can be established.
MATERIALS AND METHODS
Patients and clinicopathological features
A retrospective review of a prospectively maintained 
database for gastric cancer revealed a total of 6125 
consecutive patients who underwent gastrectomy for 
primary gastric cancer from January 2005 to December 
2010. We excluded patients from the analysis who fulfilled 
the following criteria: (1) received neoadjuvant therapy 
(n = 102); (2) received a preoperative or postoperative 
diagnosis of distant metastasis (n = 153); (3) did nothave 
adenocarcinoma (n = 101); and (4) were not examined 
with CT following a stomach cancer-specific protocol (n 
= 417). Finally, 5352 patients were included for analysis. 
(Figure 1) This study was reviewed and approved by the 
Institutional Review Board of Severance Hospital, Yonsei 
University Health System (4-2013-0510).
The demographics of the patients, including age, 
sex, and pathological features of histology, size, location, 
presence of ulceration, and gross type on endoscopy, 
were evaluated. Histologic types were classified into 
two groups: differentiated, which included papillary, 
well-differentiated, or moderately-differentiated 
adenocarcinoma, and undifferentiated, which included 
poorly-differentiated or undifferentiated adenocarcinoma, 
signet ring cell carcinoma, and mucinous carcinoma. 
Gross types were classified into two groups based on 
endoscopic finings as EGC or AGC [18].
Stomach cancer-specific CT protocol
Preoperative staging was conducted based on CT 
scans taken in accordance with a stomach cancer-specific 
protocol. The equipment was a 16- or 64-detector row CT 
scan (Sensation 16 or 64; Siemens Medical Solutions, 
Germany). Each patient fasted for 4 hours before the CT 
examination. Before the CT scan, patients were injected 
with 10mg of butylscopolamine bromide (Buscopan; 
BoehringerIngelheim, Germany) to minimize bowel 
peristalsis and to induce hypotonia. Images were acquired 
from the level of the diaphragm to the symphysis pubis 
with detector collimations of 16×0.75mm or 64×0.6mm. 
Other scanning parameters were as follows: 160 mAs; 
120 kVp; table speed of 24 mm per rotation; and gantry 
rotation time of 0.5 seconds. For gastric distention, 
we initially used water as an oral contrast agent (800-
1000ml). Beginning in January 2007, we used two packs 
of effervescent granules for gastric distention. CT scans 
were obtained with the patient in the supine position 
irrelevant to the ingested oral contrast. All patients 
received 120-150ml of contrast medium intravenously 
using an automatic injector at a rate of 3-4ml/s. Images 
were acquired in the arterial and portal phases. Axial and 
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coronal images were reconstructed with a 3-mm thickness 
section and a 3-mm interval. 
Preoperative CT evaluation
The CT scans were evaluated by radiologists 
specialized in upper gastrointestinal imaging. Mural 
invasion of gastric cancer into the gastric wall was 
classified according to previously published criteria [19-
22]. A cT1 lesion was defined as non-visualization of 
an abnormal mural lesion or mucosal thickening with 
enhancement (cT1a) or visualization of a low attenuation 
stripe at the base of the lesion, corresponding to the 
submucosal layer (cT1b). A cT2-3lesion was defined as 
a thickening of the gastric wall with a loss or disruption 
of a low attenuating stripe and a clear and smooth outer 
gastric surface around the lesion. Since CT criteria for 
cT3 (subserosal layer) lesions have not been established 
and the serosal layer of the gastric wall is not visible on 
CT images, differentiation of cT2 (proper muscle layer) 
from cT3 lesions on CT images is nearly impossible. 
Thus, we defined cT2 and cT3 lesions as cT2-3. All cT4a 
lesions demonstrated nodular or irregular outer borders 
of a thickened gastric wall or perigastric fat infiltration, 
and all cT4b lesions showed the changes described for 
cT4a lesions in addition to extension into adjacent organs. 
Positive lymph nodes were identified on the basis of a size 
larger than 8 mm along the short axis [23]. According to 
this criterion, nodal status on CT scans was classified as 
follows: cN-, no significant lymph node enlargement, or 
cN+, lymph node enlargement.
Pathologic staging
Pathologic evaluation of depth of invasion was 
performed with resected surgical specimens based on 
the 7th edition of the International Union Against Cancer 
Classification (AJCC) as follows: pT1, tumor invasion of 
the mucosa and/or submucosa; pT2, tumor invasion of the 
muscularis propria; pT3, tumor invasion of the subserosa; 
pT4a, tumor penetration of the serosa; and pT4b, tumor 
invasion of adjacent structures [22, 24]. Lymph nodes 
were categorized as pN-, no lymph node metastasis, or 
pN+, more than one lymph node metastasis.
Grouping of patients
Although treatment modalities were decided by 
clinical staging, the appropriateness of the treatment 
decisions was assessed according to pathologic stage. To 
establish proper selection criteria for treatment modalities, 
we grouped patients into one of four groups (Figure 2): 
(1) the clinical early and pathological early stage (cEpE)
group, including clinical stages cT1/N-, cT1/N+, or cT2-
3/N- and pathological stages pT1/N-, pT1/N+, or pT2-
3/N-; (2) the clinical early and pathological advanced 
stage (cEpA) group, including clinical stages cT1/N-, 
cT1/N+, or cT2-3/N- and pathological stages pT2-3/
N+, pT4/N-, or pT4/N+; (3) the clinical advanced and 
pathological early stage (cApE) group, including clinical 
stages cT2-3/N+, cT4/N-, or cT4/N+ and pathological 
stages pT1/N-, pT1/N+, or pT2-3/N-; and (4) the clinical 
advanced and pathological advanced stage (cApA) group, 
including clinical stages cT2-3/N+, cT4/N-, or cT4/N+ 
and pathological stages pT2-3/N+, pT4/N-, or pT4/N+. In 
general, patients in the cEpE and cEpA groups underwent 
surgery first. Meanwhile, patients in the cApE and 
cApA groups underwent either surgery or neoadjuvant/
perioperative treatment. Between the cApE and cApA 
groups, patients in the cApA group were more likely to 
receive more appropriate treatment with accurate clinical 
staging, which we considered to reflect proper patient 
stratification. However, cApE patients may have possibly 
received inappropriate treatment, since the treatment 
modality was selected according to inaccurate preoperative 
clinical staging (i.e., improper patient stratification).
Definition of overestimation and underestimation
Overestimation of the depth of invasion (T) 
was defined as a case in which the tumor depth on 
preoperative evaluation by CT scan was deeper than 
that on final pathologic evaluation. If the tumor depth on 
preoperative evaluation by CT scan was shallower than 
that on final pathologic evaluation, T was regarded as 
being underestimated. Similarly, overestimation of nodal 
involvement (N) was defined as preoperative CT scans 
showing significant lymph nodes, despite the absence of 
an involved lymph node on final pathologic evaluation. 
Underestimation of N was defined when node-negative 
gastric cancer on CT scans exhibited the presence of 
metastatic lymph nodes in the resected specimen. For 
overall staging, overestimation and underestimation were 
defined as preoperative clinical stage that was higher or 
lower than the pathological stage, respectively.
Statistical analysis
For statistical analysis, SPSS software (version 
18.0; SPSS Inc., Chicago, IL, USA) was used. Categorical 
variables were analyzed using the chi-square test, and 
continuous data were analyzed using the Mann-Whitney 
test. For multivariate analysis, logistic regression analysis 
was used. All values of p less than 0.05 wereconsidered to 
demonstrate statistical significance.
We assessed reliability by weighted k [25]. Weighted 
k was computed to quantify agreement between the CT 
findings and final pathology. For weighted k, full weight 
was given to perfect agreement; half weight was given 
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to disagreement by one grade; and zero weight was 
given to other disagreements. The degrees of agreement 
were categorized as follows: values of 0.00-0.20, poor 
agreement; values of 0.21-0.40, fair agreement; values of 
0.41-0.60, moderate agreement; values of 0.61-0.80, good 
agreement; and values of 0.81-1.00, excellent agreement 
[26].
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